The FDA added six additional therapies to its Commissioner’s National Priority Vouchers pilot, bringing the program total to 15 drugs selected for accelerated review under a national‑interest rubric. The pilot aims to compress standard review timelines—typically 10–12 months—'to within months' for chosen therapies. Under the pilot, the agency evaluates candidates deemed critical to national health priorities; acceptance grants sponsors prioritized regulatory attention. The expansion signals the FDA’s willingness to experiment with targeted speed pathways while balancing review quality. Manufacturers and developers will weigh the operational advantages of faster review against program eligibility constraints and potential political and evidentiary scrutiny tied to the prioritization process.